Home › Compare › NICXF vs GBDC

NICXF vs GBDC: Dividend Comparison 2026

NICXF yields 666.67% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NICXF wins by $608094.88M in total portfolio value
10 years
NICXF
NICXF
● Live price
666.67%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$608115.66M
Annual income
$469,561,018,816.25
Full NICXF calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — NICXF vs GBDC

📍 NICXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNICXFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NICXF + GBDC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NICXF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NICXF
Annual income on $10K today (after 15% tax)
$56,666.67/yr
After 10yr DRIP, annual income (after tax)
$399,126,865,993.81/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, NICXF beats the other by $399,112,935,119.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NICXF + GBDC for your $10,000?

NICXF: 50%GBDC: 50%
100% GBDC50/50100% NICXF
Portfolio after 10yr
$304068.22M
Annual income
$234,788,704,039.82/yr
Blended yield
77.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

NICXF
No analyst data
Altman Z
-14.8
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NICXF buys
0
GBDC buys
0
No recent congressional trades found for NICXF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNICXFGBDC
Forward yield666.67% ✓11.85%
Annual dividend / share$2.00 ✓$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1% ✓
Portfolio after 10y$608115.66M ✓$20.78M
Annual income after 10y$469,561,018,816.25 ✓$16,389,263.41
Total dividends collected$596792.85M ✓$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: NICXF vs GBDC ($10,000, DRIP)

YearNICXF PortfolioNICXF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$77,367$66,666.67$12,490$1,790.28+$64.9K → NICXF
2$564,818$482,035.31$16,522$3,157.73+$548.3K → NICXF
3$3,893,246$3,288,890.67$23,578$5,898.68+$3.87M → NICXF
4$25,352,760$21,186,987.16$37,115$11,886.75+$25.32M → NICXF
5$156,070,781$128,943,327.59$66,136$26,423.57+$156.00M → NICXF
6$908,837,800$741,842,064.29$137,257$66,491.44+$908.70M → NICXF
7$5,009,769,782$4,037,313,336.56$341,734$194,868.54+$5009.43M → NICXF
8$26,159,339,258$20,798,885,591.56$1,050,788$685,133.02+$26158.29M → NICXF
9$129,490,317,125$101,499,824,118.87$4,099,314$2,974,971.01+$129486.22M → NICXF
10$608,115,658,140$469,561,018,816.25$20,775,530$16,389,263.41+$608094.88M → NICXF

NICXF vs GBDC: Complete Analysis 2026

NICXF — Stock

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.

Full NICXF Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this NICXF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NICXF vs SCHDNICXF vs JEPINICXF vs ONICXF vs KONICXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.